Villoo Morawala-Patell

The company raised more than 70 million USD in venture capital before largely collapsing around 2012 with a failed public offering, the exit of senior executives, the shutdown of manufacturing, and the cessation of most research activities.

Avesthagen later undertook research and development initiatives that include The 10,000 Avestagenome Project which led to the sequencing the first complete Zoroastrian-Parsi mitochondrial reference genome and genetic signatures of an endogamous non-smoking population with the hope of identifying disease specific markers in the space of cancers, neurodegenerative diseases and rare diseases.